KOSDAQBiotech & Pharma253840

Sugentech

₩3,870▲ 2.65%2026-11-18 close
Market Cap
₩64.8B
Turnover
₩98,343,415
Volume
30K
Shares out.
16.7M
PER
—
PBR
0.9×
EPS
-₩1,531
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Two quarters of sales growth, losses persist

Sugentech's quarterly revenue rose for two straight quarters into Q3 2026 and operating losses narrowed, but losses have persisted for three consecutive years since 2023 and operating cash outflows continue.

  1. 1

    Revenue for 2025 was KRW 9.42 billion, down 6.7% from the prior year, while the operating loss narrowed to KRW 18.8 billion from KRW 22 billion in 2024.

  2. 2

    Q3 2026 revenue was KRW 3.45 billion, up 132.9% year on year, and the operating loss narrowed to KRW 3.29 billion.

  3. 3

    Across the four quarters from Q4 2025 to Q3 2026, the controlling-shareholder net loss totals KRW 23.4 billion.

  4. 4

    Overseas, the CE-IVDR-certified S-Blot 3 and a China joint venture technology-transfer deal are the main confirmed developments.

  5. 5

    Operating cash flow has been negative every year since 2023, reaching KRW -14.6 billion in 2025.

02

Business structure

Sugentech is an in-vitro diagnostics company founded in 2011 that moved to KOSDAQ in 2019 as a technology-growth company. Built on BIO, NANO, IT and AI convergence technologies, it runs multiplex immunoblot, point-of-care testing (POCT), digital healthcare and health and beauty businesses.

Its growth strategy links these three platforms into a prevention, diagnosis and management healthcare ecosystem. Its key products are the SGTi-Allergy Screen PLUS allergy test reagent and the S-Blot 3 PLUS immunoblot reader, both undergoing clinical evaluation to improve accuracy and cost efficiency.

Government and public procurement buyers form a visible customer base: in February 2022 the company disclosed a KRW 22 billion self-test kit supply contract through the Public Procurement Service, and reports described Spain's health ministry concluding a supply deal after its own clinical testing of Sugentech products.

Overseas, the CE-IVDR-certified S-Blot 3 is being used to widen distribution in Europe and India, and the company exhibited at WHX Labs Dubai 2026. Its femtech subsidiary is extending the company into hormone data platforms, and the subsidiary hosted the Korea Femtech Summit 2026 on June 30, 2026.

The in-vitro diagnostics market is crowded, so platform strength and certification scope shape the entry conditions in each market. Product-level and segment revenue shares are best checked against the revenue breakdown in the annual business report.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.5B-₩4.8B−326.6%
2025Q4₩2.9B-₩5.1B−178.1%
2026Q1₩2.3B-₩4.7B−199.6%
2026Q2₩3.1B-₩4.2B−137.0%
2026Q3₩3.5B-₩3.3B−95.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩101.4B₩25B₩26.7B24.6%19.0%23.3%
2023₩7.1B-₩22.8B-₩17.2B−319.1%−15.3%18.4%
2024₩10.1B-₩22B-₩15.2B−218.1%−15.6%10.6%
2025₩9.4B-₩18.8B-₩23.3B−199.9%−30.6%28.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 101.4 billion in 2022 to KRW 7.13 billion in 2023, down 93.0%, then recovered to KRW 10.1 billion in 2024, up 41.6%, before declining 6.7% to KRW 9.42 billion in 2025. Among 2022 to 2025, 2022 was the largest year and 2023 the smallest.

Operating profit of KRW 25 billion in 2022 (operating margin 24.6%) turned into an operating loss of KRW 22.8 billion in 2023, and the loss then narrowed to KRW 22 billion in 2024 and KRW 18.8 billion in 2025.

Losses have been recorded for three years running from 2023 to 2025, with operating margins of -319.1%, -218.1% and -199.9%.

Net income attributable to controlling shareholders moved from KRW 26.7 billion in 2022 to a loss of KRW 17.2 billion in 2023, a loss of KRW 15.2 billion in 2024, and a wider loss of KRW 23.3 billion in 2025.

Net loss including non-controlling interests, at KRW 23.5 billion in 2025, is a different figure from the controlling-shareholder result.

The 2022 revenue peak appears to have leaned on COVID-19 testing contracts, and a February 2022 disclosure of a KRW 22 billion self-test kit contract was reported as roughly 28% of the prior year's sales.

Operating cash flow went from KRW 30.4 billion in 2022 to KRW -12.2 billion in 2023, KRW -7.52 billion in 2024 and KRW -14.6 billion in 2025.

At the end of 2025, total equity was KRW 76.5 billion (KRW 76.3 billion attributable to controlling shareholders) and total liabilities were KRW 21.7 billion, with the debt ratio rising from 10.6% in 2024 to 28.3% in 2025.

Quarterly revenue went from KRW 1.48 billion in Q3 2025 and KRW 2.87 billion in Q4 2025 to KRW 2.35 billion in Q1 2026, then KRW 3.08 billion in Q2 and KRW 3.45 billion in Q3 2026, rising for two consecutive quarters.

Operating losses narrowed from KRW 4.84 billion in Q3 2025 and KRW 5.12 billion in Q4 2025 to KRW 4.68 billion, KRW 4.23 billion and KRW 3.29 billion across Q1 to Q3 2026.

The controlling-shareholder net loss, however, widened to KRW 4.19 billion in Q3 2026 from KRW 3.79 billion in Q2, and the four quarters from Q4 2025 to Q3 2026 total KRW 23.4 billion. Third-party compilation shows first-half 2026 revenue up 7.3% year on year, operating loss up 0.5% and net loss down 3.7%.

05

Industry analysis

Company-analysis sources describe the in-vitro diagnostics reagent and kit market as growing since COVID-19, as seasonal infectious disease prevalence has risen and interest in preventive and early diagnosis has grown.

Aging populations and digital technology advances are cited as drivers of demand for point-of-care testing.

Sugentech's revenue, however, has not moved in step with market growth: revenue of KRW 101.4 billion in 2022 fell to KRW 7.13 billion in 2023, which suggests shifts in infectious disease testing demand were reflected.

Whether the two consecutive quarterly revenue gains in 2026 come from recurring demand rather than outbreak-driven orders can be checked against product-level sales in the business report.

Competitively, the company stresses its combination of multiplex immunoblot and POCT platforms, but many companies compete across molecular and immunoassay diagnostics. Overseas entry depends on country-level certification and government clinical testing.

Reports of Spain's health ministry concluding a supply deal after its own clinical testing illustrate how government evaluation can lead to contracts. The CE-IVDR certification of S-Blot 3 meets the conditions for European market entry.

Precise comparisons of revenue scale and share against peers are most accurate when each company's DART periodic reports are read side by side.

06

Outlook

The China business centers on a local joint venture.

According to the Q1 2026 quarterly report, the arrangement covers an 800 million yuan JV stake, a 1 billion yuan milestone and a royalty of 1.5% of sales, and the JV receives production and quality-control technology for the Surearly product along with exclusive sales rights in China.

Milestone receipts and royalty size depend on Chinese sales, so whether local sales begin is the next checkpoint. Clinical evaluation of the allergy test reagent and the S-Blot 3 PLUS is under way, and how these product improvements feed into the revenue mix is a key point to watch.

In femtech, the subsidiary shared a global vision for a couples' prenatal care platform ahead of a planned US market entry. On the public procurement side, reports say the pregnancy test kit was placed on a UNICEF long-term arrangement, opening a channel to supply UN agencies for up to five years.

Whether the revenue gain in Q3 2026 continues into Q4 is the first checkpoint for the quarterly trend. It is also worth watching whether operating losses keep narrowing and whether the controlling-shareholder net loss moves in the same direction.

The next scheduled periodic filing is the 2026 annual business report, which will set out full-year operating margin and cash flow figures on the DART basis.

07

Valuation

PER
—
PBR
0.9×
ROE
-30.8%
EPS
-₩1,531
BPS
₩4,199
Dividend per share
₩0

Because the controlling-shareholder net loss has accumulated over the last four quarters, the price-to-earnings ratio cannot be calculated. With earnings-based multiples out of reach, the price-to-book ratio, which measures the stock against net assets, becomes the starting point for relative comparison.

The price-to-book ratio sits below 1x, and at the end of 2025 controlling shareholders' equity of KRW 76.3 billion made up nearly all of total equity of KRW 76.5 billion, so book value anchors the comparison. The dividend yield is effectively nil, so little income comes from dividends.

In the multi-year record, the switch from profit in 2022 to losses from 2023 is the largest variable in interpreting the multiple.

A low multiple relative to net assets can be read as the market discounting continued losses, and views also exist that a continued narrowing of operating losses could support a different reading.

Multiples are best read alongside the disclosed earnings trend, and once the 2026 annual business report is filed, the annual profit and loss can be used to reassess them.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Narrowing operating losses and quarterly sales recovery

Operating losses fell from KRW 5.12 billion in Q4 2025 to KRW 4.68 billion in Q1 2026, KRW 4.23 billion in Q2 and KRW 3.29 billion in Q3. Q3 2026 revenue of KRW 3.45 billion was up 132.9% year on year. Even amid three years of losses, the narrowing quarterly operating loss points to room for margin improvement.

Overseas certification and China technology transfer

The S-Blot 3 holds CE-IVDR certification, which provides a basis for sales in Europe.

The China JV receives production and quality-control technology for the Surearly product along with exclusive sales rights, with total contract value built from an 800 million yuan JV stake, a 1 billion yuan milestone and a 1.5% royalty on sales. Overseas revenue share should be confirmed in the business report.

Diversifying diagnostic demand and new areas

The allergy test reagent is undergoing clinical evaluation aimed at better accuracy, convenience and cost efficiency. Reports say the pregnancy test kit was placed on a UNICEF long-term arrangement, opening a channel to supply UN agencies for up to five years.

The femtech subsidiary's hormone data platform could become a demand base separate from infectious disease testing.

09

Bear factors

Three years of losses and cash outflows

Operating losses have continued from 2023 to 2025, and the controlling-shareholder net loss widened to KRW 23.3 billion in 2025 from KRW 15.2 billion in 2024. Operating cash outflow reached KRW 14.6 billion in 2025, larger than the KRW 7.52 billion in 2024.

Across the last four quarters the controlling-shareholder net loss totals KRW 23.4 billion, so the narrowing operating loss has not translated directly into a smaller net loss.

Revenue history shaped by infectious disease demand

Revenue fell 93.0% from KRW 101.4 billion in 2022 to KRW 7.13 billion in 2023 and declined a further 6.7% in 2025. A February 2022 self-test kit contract of KRW 22 billion was reported as about 28% of the prior year's sales, which suggests heavy reliance on infectious disease demand. Quarterly revenue has risen in 2026 but remains around KRW 3 billion a quarter, a small absolute scale.

Wider net losses and share count changes

The controlling-shareholder net loss jumped to KRW 11.2 billion in Q4 2025, and the Q3 2026 loss of KRW 4.19 billion was larger than in the prior quarter. A stock option grant filing was disclosed on May 27, 2026, and two officer and major shareholder holding reports were filed on July 20, 2026. Changes in share count and ownership could affect the pace at which per-share earnings recover.

10

Risk factors

Liquidity and cash flow

Operating cash flow has been negative every year since 2023, reaching KRW -14.6 billion in 2025. Total equity of KRW 76.5 billion and liabilities of KRW 21.7 billion show some capacity to absorb losses, but continued losses would steadily erode equity. Whether operating cash flow improves should be checked in the 2026 annual business report.

Demand volatility and business concentration

Revenue has moved sharply with infectious disease testing demand and government procurement timing. As the 93.0% drop in 2023 shows, a business leaning on specific contracts or procurement channels can see revenue gaps. Milestone and royalty income from the China JV depends on local sales, so its timing is uncertain.

Shareholder structure and dilution

As of September 16, 2026, the largest shareholder group led by Son Mi-jin held 14.55% and treasury shares accounted for 8.68%, according to WiseReport. Given the stock option filing and officer and major shareholder holding reports, periodic disclosures should be tracked for changes in share count and ownership. Use of treasury shares would also affect the free float.

11

What to watch next

  1. December 31, 2026

    The 2026 fiscal year closes. Whether Q4 revenue holds near the KRW 3.45 billion of Q3 and whether the operating loss narrows below KRW 3.29 billion will set the starting point for the full-year trend.

  2. March 31, 2027

    The deadline for the 2026 annual business report. Full-year revenue, operating loss and operating cash flow will be fixed in the periodic filing, and the product-level reasons for the 2023 revenue drop and the rise in the debt ratio to 28.3% should be checked.

  3. Around May 15, 2027

    The deadline for the Q1 2027 quarterly report. Whether the revenue gains seen in Q2 and Q3 2026 continue, and whether the controlling-shareholder net loss narrows in step with the operating loss, will be the checks.

12

Overall view

Sugentech is an in-vitro diagnostics company founded in 2011, and on a disclosed basis it has recorded operating and net losses for three consecutive years since 2023.

Revenue fell from KRW 101.4 billion in 2022 to KRW 7.13 billion in 2023, then reached KRW 10.1 billion in 2024 and KRW 9.42 billion in 2025, and quarterly revenue has risen for two consecutive quarters in 2026.

The operating loss narrowed from KRW 4.84 billion in Q3 2025 to KRW 3.29 billion in Q3 2026, but the controlling-shareholder net loss totals KRW 23.4 billion over the last four quarters and operating cash outflows have continued since 2023.

On the business side, the multiplex immunoblot and POCT platforms, the CE-IVDR-certified device, the China JV technology transfer and the femtech subsidiary are confirmed through filings and reports.

On the other side, revenue has swung sharply with infectious disease testing demand, and the debt ratio rose to 28.3% at the end of 2025 from 10.6% in 2024. With no price-to-earnings ratio available, valuation is most practically compared on price-to-book and book value.

The next checkpoints are the full-year operating margin in the 2026 annual business report, the revenue trend in Q1 2027, and whether milestone payments from the China JV occur.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. pmstoryhub.com
  2. comp.wisereport.co.kr
  3. kuksoolone.com
  4. kind.krx.co.kr
  5. sedaily.com
  6. saramin.co.kr
  7. news1.kr
  8. etoday.co.kr
  9. hankyung.com
  10. etoday.co.kr
  11. etoday.co.kr
  12. etoday.co.kr
  13. etoday.co.kr
  14. pharmnews.com
  15. ajunews.com
  16. etoday.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis